This global study for people with relapsing remitting MS is evaluating daclizumab: a new investigational therapy that may help control specific parts of the immune system that often attack nerves in MS.
Learn more about DECIDE, see what participation involves — and find out if taking part in this clinical study may be the right decision for you.
..
===========================================================
.
On the 4th Wednesday of each month
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions
.
Your donation will Help us to educate
“MS Views and News” is a 501©(3) not for profit organization as recognized by the Internal Revenue Service
.. All contributions are tax deductible to the fullest extent allowed by law
.===========================================================
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews